Literature DB >> 17101262

Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis.

Zahoor Ahmad1, Sadhna Sharma, G K Khuller, Pushpendra Singh, Jaya Faujdar, V M Katoch.   

Abstract

This study evaluated the antimycobacterial activity of econazole against multidrug-resistant (MDR) strains of Mycobacterium tuberculosis. The minimum inhibitory concentration (MIC(90)) and minimum bactericidal concentration (MBC(>99.99)) against MDR strains were found to be 0.120-0.125 microg/mL and 0.125-0.150 microg/mL, respectively, demonstrating the antimycobacterial potential of econazole.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17101262     DOI： 10.1016/j.ijantimicag.2006.07.028

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  19 in total

1.  In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.

Authors:  Lucio Vera-Cabrera; Mayra Paola Campos-Rivera; Wendy G Escalante-Fuentes; Michael J Pucci; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

2.  The Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infection.

Authors:  Kirsty J McLean; Pierre Lafite; Colin Levy; Myles R Cheesman; Natalia Mast; Irina A Pikuleva; David Leys; Andrew W Munro
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

3.  Advances in the treatment of pulmonary tuberculosis.

Authors:  Xia Zhang; Jing Guo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

4.  An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae.

Authors:  Christopher R J Agnew; Andrew G S Warrilow; Nicholas M Burton; David C Lamb; Steven L Kelly; R Leo Brady
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

Review 5.  Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Trends Microbiol       Date:  2011-09-15       Impact factor: 17.079

6.  Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121: insights from biochemical studies and crystal structures.

Authors:  Matthieu Fonvielle; Marie-Hélène Le Du; Olivier Lequin; Alain Lecoq; Mickaël Jacquet; Robert Thai; Steven Dubois; Guillaume Grach; Muriel Gondry; Pascal Belin
Journal:  J Biol Chem       Date:  2013-04-25       Impact factor: 5.157

Review 7.  Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Paul R Ortiz de Montellano
Journal:  J Inorg Biochem       Date:  2018-01-12       Impact factor: 4.155

8.  Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1.

Authors:  Hugues Ouellet; Petrea M Kells; Paul R Ortiz de Montellano; Larissa M Podust
Journal:  Bioorg Med Chem Lett       Date:  2010-11-05       Impact factor: 2.823

9.  Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.

Authors:  Kirsty J McLean; Paul Carroll; D Geraint Lewis; Adrian J Dunford; Harriet E Seward; Rajasekhar Neeli; Myles R Cheesman; Laurent Marsollier; Philip Douglas; W Ewen Smith; Ida Rosenkrands; Stewart T Cole; David Leys; Tanya Parish; Andrew W Munro
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

10.  Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.

Authors:  Larissa M Podust; Hugues Ouellet; Jens P von Kries; Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.